Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,984 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.
Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A, Miyamoto Y, Mizunuma N, Lenz HJ. Matsusaka S, et al. Among authors: cao s. Pharmacogenomics J. 2018 Apr;18(2):262-269. doi: 10.1038/tpj.2017.9. Epub 2017 Apr 11. Pharmacogenomics J. 2018. PMID: 28398355 Free PMC article.
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ. Berger MD, et al. Among authors: cao s. Eur J Cancer. 2017 May;77:13-20. doi: 10.1016/j.ejca.2017.02.020. Epub 2017 Mar 26. Eur J Cancer. 2017. PMID: 28347919 Free PMC article. Clinical Trial.
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ. Schirripa M, et al. Among authors: cao s. Int J Cancer. 2017 Jul 15;141(2):383-392. doi: 10.1002/ijc.30715. Epub 2017 May 10. Int J Cancer. 2017. PMID: 28369940 Free PMC article. Clinical Trial.
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.
Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ. Schirripa M, et al. Among authors: cao s. PLoS One. 2018 Mar 9;13(3):e0193640. doi: 10.1371/journal.pone.0193640. eCollection 2018. PLoS One. 2018. PMID: 29522543 Free PMC article.
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.
Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Lonardi S, Bergamo F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ. Suenaga M, et al. Among authors: cao s. Pharmacogenomics J. 2018 Sep;18(5):623-632. doi: 10.1038/s41397-018-0030-8. Epub 2018 Jun 21. Pharmacogenomics J. 2018. PMID: 29925895 Free PMC article.
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
Suenaga M, Schirripa M, Cao S, Zhang W, Cremolini C, Lonardi S, Okazaki S, Berger MD, Miyamoto Y, Soni S, Barzi A, Yamaguchi T, Loupakis F, Falcone A, Lenz HJ. Suenaga M, et al. Among authors: cao s. Pharmacogenomics J. 2021 Jun;21(3):285-295. doi: 10.1038/s41397-021-00207-x. Epub 2021 Feb 4. Pharmacogenomics J. 2021. PMID: 33542444
Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ. Matsusaka S, et al. Among authors: cao s. Clin Cancer Res. 2016 Jul 1;22(13):3218-26. doi: 10.1158/1078-0432.CCR-15-2422. Epub 2016 Feb 2. Clin Cancer Res. 2016. PMID: 26839145 Free PMC article. Clinical Trial.
TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W, Mizunuma N, Lenz HJ. Matsusaka S, et al. Among authors: cao s. Mol Cancer Ther. 2016 Jun;15(6):1405-11. doi: 10.1158/1535-7163.MCT-15-0751. Epub 2016 Mar 16. Mol Cancer Ther. 2016. PMID: 26983880 Free PMC article.
Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer.
Sunakawa Y, Cao S, Berger MD, Matsusaka S, Yang D, Zhang W, Ning Y, Parekh A, Stremitzer S, Mendez A, Okazaki S, Wakatsuki T, Azuma M, Shimada K, Watanabe M, Koizumi W, Wu AH, Lenz HJ. Sunakawa Y, et al. Among authors: cao s. Pharmacogenomics J. 2017 Jan;17(1):36-41. doi: 10.1038/tpj.2015.77. Epub 2015 Oct 27. Pharmacogenomics J. 2017. PMID: 26503819 Free PMC article.
7,984 results